Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

分组1 - Lyra Therapeutics reported a quarterly loss of $5.51 per share, which was better than the Zacks Consensus Estimate of a loss of $5.79, and an improvement from a loss of $14.5 per share a year ago, resulting in an earnings surprise of +4.84% [1] - The company posted revenues of $0.18 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 26.21%, although this was a decline from year-ago revenues of $0.6 million [2] - Lyra Therapeutics shares have declined approximately 35.4% year-to-date, contrasting with the S&P 500's gain of 8.4% [3] 分组2 - The earnings outlook for Lyra Therapeutics is mixed, with the current consensus EPS estimate for the upcoming quarter at -$6.52 on revenues of $0.15 million, and -$2.02 on revenues of $0.45 million for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the top 35% of over 250 Zacks industries, suggesting that companies in the top half tend to outperform those in the bottom half by more than 2 to 1 [8]